Article Information
History
- October 28, 2021.
Article Versions
- Version 1 (October 27, 2021 - 19:49).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Hannah G. Rosenblum, MD1,2,
- Julianne M. Gee, MPH1,*,
- Ruiling Liu, PhD1,
- Paige L. Marquez, MSPH1,
- Bicheng Zhang, MS1,
- Penelope Strid, MPH1,
- Winston E. Abara, MD1,
- Michael M. McNeil, MD, MPH1,
- Tanya R. Myers, PhD1,
- Anne M. Hause, PhD, MSPH1,
- John R. Su, MD, PhD, MPH1,
- Bethany Baer, MD3,
- David Menschik, MD, MPH3,
- Lauri E. Markowitz, MD1,
- Tom T. Shimabukuro, MD, MPH, MBA1 and
- David K. Shay, MD, MPH1
- 1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia
- 2Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia
- 3Food and Drug Administration, Silver Spring, Maryland
- ↵*Corresponding author: Julianne Gee, eocevent416{at}cdc.gov
Posted October 28, 2021.
Safety Monitoring of mRNA Vaccines Administered During the Initial 6 Months of the U.S. COVID-19 Vaccination Program: Reports to Vaccine Adverse Events Reporting System (VAERS) and v-safe
